With the aim of investigating the influence of trisomy 21 on the expression of heritable morphological features, we recorded the palmar and plantar dermatoglyphic patterns in 48 children with Down syndrome (DS), in both their parents, and, as a control, in 57 of their siblings. Using the Kendall tau rank correlation test, a considerable parental influence on the frequency of true patterns in the interdigital areas (IDA) III and IV of the palms (P = 0.3%) and soles (P = 1.0% and 3.8%, respectively) is demonstrated for the control siblings. In the children with DS, this influence is discernible as well, although with no statistical significance. A greater number of families may be required to settle the question.   

1.
Ayme S, Mattei M-G, Mattei JF, Aurran Y, Giraud F: Dermatoglyphics in parents of children with trisomy 21. Clin Genet 15:78–84 (1979).
2.
Bersu ET: Anatomical analysis of the developmental effects of aneuploidy in man: the Down syndrome. Am J med Genet 5:399–420 (1980).
3.
Bortz J, Lienert GA: Kurzgefasste Statistik für die klinische Forschung: Ein praktischer Leitfaden für die Analyse kleiner Stichproben (Springer-Verlag, Berlin 1998).
4.
Brook CGD, Gasser T, Werder EA, Prader A, Vanderschueren-Lodewykx MA: Height correlations between parents and mature offspring in normal subjects and in subjects with Turner’s and Klinefelter’s and other syndromes. Ann hum Biol 4:17–22 (1977).
5.
Bryant JL, Emanuel I, Huang S-W, Kronmal R, Lo J: Dermatoglyphs of Chinese children with Down’s syndrome. J med Genet 7:338–344 (1970).
6.
Epstein CJ: The Consequences of Chromosome Imbalance: Principles, Mechanisms, and Models (Cambridge University Press, London, 1986).
7.
Epstein CJ: Aneuploidy and morphogenesis, in Epstein CJ (ed): The Morphogenesis of Down Syndrome, pp 1–18 (Wiley-Liss, New York 1991).
8.
Falconer DS, Mackay TFC: Introduction to Quantitative Genetics, 4th Ed (Longman, Harlow 1996).
9.
Fraser FC, Sadovnick AD: Correlation of IQ in subjects with Down syndrome and their parents and sibs. J ment Defic Res 20:179–182 (1976).
10.
Garcia-Minaur S, Castro V, Ayme S: Associated anomalies in trisomy 21. EUROCAT data, 1980–1997. Eur J hum Genet 8(Suppl 1):64 (2000).
11.
Herzberger G, Kümmerle S: Die Vererbung von Hautleistenmustern beim Down-Syndrom: Ein Modell für die Pathogenese der Trisomien. Medical Dissertation, Frankfurt/Main (1993).
12.
Holt SB: The Genetics of Dermal Ridges (Charles Thomas, Springfield, IL 1968).
13.
Källen B, Mastroiacovo P, Robert E: Major congenital malformations in Down syndrome. Am J med Genet 65:160–166 (1996).
14.
Katznelson MB, Bejerano M, Yakovenko K, Kobyliansky E: Relationship between genetic anomalies of different levels and deviations in dermatoglyphic traits. IV. Dermatoglyphic peculiarities in males and females with Down syndrome: family study. Anthropol Anz 57:193–255 (1999).
15.
Korenberg JR, Chen X-N, Schipper R, Sun Z, Gonsky R, Gerwehr S, Carpenter N, Daumer C, Dignan P, Disteche C, Graham Jr JM, Hugdins L, McGillivray B, Miyazaki K, Ogasawara N, Park JP, Pagon R, Pueschel S, Sack G, Say B, Schuffenhauer S, Soukup S, Yamanaka T: Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc natl Acad Sci, USA 91:4997–5001 (1994).
16.
Langenbeck U: Developmental pathogenesis of chromosome disorders: a final word. Am J med Genet 31:479–80 (1988).
17.
Langenbeck U, Herzberger G, Kümmerle S, Rodewald A: Vererbung der Hautleistenmuster des Grosszehenballens beim Down-Syndrom. 6. Tagung Klinische Genetik, S. 47 (Institut für Anthropologie und Humangenetik, Erlangen 1988).
18.
Loesch D: Genetics of dermatoglyphic patterns on palms. Ann hum Genet 34:277–293 (1971).
19.
Loesch D: Genetical studies of sole and palmar dermatoglyphics. Ann hum Genet 37:405–420 (1974).
20.
Loesch D: Dermatoglyphic studies in the parents of trisomy 21 children. I. Distribution of dermatoglyphic discriminants. Hum Hered 31:201–207 (1981).
21.
Malich S, Largo RH, Schinzel A, Molinari L, Eiholzer U: Phenotype heterogeneity of growth and psychometric intelligence in Prader-Willi syndrome: variable expression of a contiguous gene syndrome or parent-child resemblance? Am J med Genet 91: 208–304 (2000).
22.
Reed T: Dermatoglyphic findings in Down syndrome: a summary of over 700 cases, in Epstein CJ (ed): The Morphogenesis of Down syndrome, pp 277–293 (Wiley-Liss, New York 1991).
23.
Rodewald A, Bar M, Zankl M, Reicke S, Zang KD: Dermatoglyphic studies in parents of children with trisomy 21: detection of hidden mosaicism and its role in genetic counselling, in Bartsocas CS (ed): Progress in Dermatoglyphic Research, pp 371–384 (Alan R Liss, New York 1982).
24.
Rodewald-Rudescu A: Das Hautleistensystem beim Down-Syndrom (Biol. Diss., München, 1974).
25.
Schaumann B, Alter M: Dermatoglyphics in Medical Disorders (Springer-Verlag, New York 1976).
26.
Shapiro BL: The pathogenesis of aneuploid phenotypes: the fallacy of explanatory reductionism. Am J med Genet 33:146–150 (1989).
27.
Shiono H, Kadowaki J, Kasahara S: Dermatoglyphics of Down syndrome in Japan. Tohoku J exp Med 99:107–113 (1969).
28.
Torfs CP, Christianson RE: Anomalies in Down syndrome individuals in a large population-based registry. Am J med Genet 77:431–438 (1998).
29.
Torfs CP, Christianson RE: Maternal risk factors and major associated defects in infants with Down syndrome. Epidemiology 10:264–270 (1999).
30.
Walker NF: The use of dermal configurations in the diagnosis of mongolism. Pediatr Clin N Am 5:531–543 (1958).
31.
Wichmann D: Zur Genetik des Hautleistensystems der Fusssohle. Z Morph Anthrop 47:331–381 (1956).
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.